CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
61.91
+1.54 (2.55%)
Mar 6, 2026, 3:57 PM EST - Market open
CG Oncology Employees
CG Oncology had 142 employees as of December 31, 2025. The number of employees increased by 29 or 25.66% compared to the previous year.
Employees
142
Change (1Y)
29
Growth (1Y)
25.66%
Revenue / Employee
$28,451
Profits / Employee
-$1,133,768
Market Cap
5.23B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 142 | 29 | 25.66% |
| Dec 31, 2024 | 113 | 52 | 85.25% |
| Dec 31, 2023 | 61 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,769 |
| PTC Therapeutics | 991 |
| Amicus Therapeutics | 511 |
| CRISPR Therapeutics AG | 393 |
| Mirum Pharmaceuticals | 372 |
| Immunovant | 362 |
| Apogee Therapeutics | 196 |
| Scholar Rock Holding | 128 |
CGON News
- 7 days ago - CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates - GlobeNewsWire
- 11 days ago - CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 7 weeks ago - CG Oncology, Inc. (CGON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene - Seeking Alpha
- 2 months ago - CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC - GlobeNewsWire
- 2 months ago - CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - CG Oncology Undervalued Going Into A Busy 2026 - Seeking Alpha
- 3 months ago - New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer - GlobeNewsWire